Comparative Pharmacology
Head-to-head clinical analysis: RIMANTADINE HYDROCHLORIDE versus TYZEKA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIMANTADINE HYDROCHLORIDE versus TYZEKA.
RIMANTADINE HYDROCHLORIDE vs TYZEKA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rimantadine is a tricyclic amine antiviral that inhibits influenza A virus replication by blocking the M2 proton ion channel, preventing viral uncoating and release of viral RNA into host cells.
Telbivudine is a synthetic thymidine nucleoside analogue with activity against hepatitis B virus (HBV). It is phosphorylated intracellularly to the active triphosphate form, which competes with natural thymidine triphosphate for incorporation into viral DNA, causing chain termination and inhibition of HBV DNA polymerase (reverse transcriptase).
100 mg orally twice daily for 7 days; initiate within 48 hours of symptom onset.
600 mg orally once daily
None Documented
None Documented
25.4 hours (range 13–65 h); prolonged in elderly (38 h) and severe renal impairment (CrCl <10 mL/min: up to 130 h).
Terminal elimination half-life is approximately 15 hours (range 12-20 hours) in patients with normal renal function; half-life is prolonged in renal impairment, requiring dose adjustment.
Renal: 75% unchanged; fecal: <10%; biliary: minimal. Total clearance 2.5 mL/min/kg.
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal excretion accounts for approximately 60%.
Category A/B
Category C
Antiviral
Antiviral, Hepatitis B